Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Bio-Techne Corp

Healthcare US TECH

52.82USD
-2.05(3.74%)

Last update at 2026-03-10T20:00:00Z

Day Range

52.7754.87
LowHigh

52 Week Range

51.6189.50
LowHigh

Fundamentals

  • Previous Close 54.87
  • Market Cap12510.67M
  • Volume2778218
  • P/E Ratio64.54
  • Dividend Yield0.40%
  • EBITDA326.30M
  • Revenue TTM1154.28M
  • Revenue Per Share TTM7.32
  • Gross Profit TTM 770.22M
  • Diluted EPS TTM1.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 338.66M 301.39M 148.18M 276.48M 112.02M
Minority interest -0.17900M 8.95M 8.26M 8.26M 8.26M
Net income 285.26M 272.05M 140.41M 229.30M 96.07M
Selling general administrative 352.44M 339.00M 289.92M 240.88M 236.87M
Selling and marketing expenses 25.94M 33.77M 35.03M 19.70M 27.49M
Gross profit 769.82M 756.50M 632.85M 483.19M 473.49M
Reconciled depreciation 107.24M 101.07M 87.75M 82.74M 78.17M
Ebit 298.94M 296.59M 149.55M 74.68M 68.55M
Ebitda 406.18M 397.66M 237.30M 157.42M 146.72M
Depreciation and amortization 107.24M 101.07M 87.75M 82.74M 78.17M
Non operating income net other 50.93M 16.11M -75.16900M 138.25M -12.99900M
Operating income 298.94M 296.59M 149.55M 74.68M 125.58M
Other operating expenses 837.76M 809.01M 693.74M 581.27M 567.29M
Interest expense -11.21500M 11.31M 13.95M 19.20M 21.70M
Tax provision 53.22M 38.29M 8.59M 47.18M 15.94M
Interest income 3.41M 0.79M 0.47M 0.60M 0.57M
Net interest income -7.80500M -10.51500M -13.47900M -18.59200M -21.13600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 53.22M 38.29M 8.59M 47.18M 15.94M
Total revenue 1136.70M 1105.60M 931.03M 738.69M 714.01M
Total operating expenses 470.87M 459.91M 395.55M 325.77M 326.77M
Cost of revenue 366.89M 349.10M 298.18M 255.50M 240.51M
Total other income expense net 39.72M 4.80M -1.37400M 201.79M 43.47M
Discontinued operations - - - - -
Net income from continuing ops 285.44M 263.10M 139.59M 229.30M 96.07M
Net income applicable to common shares 285.26M 272.05M 140.41M 229.07M 95.97M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 2638.69M 2294.80M 2262.96M 2027.59M 1884.41M
Intangible assets 534.64M 531.52M 615.97M 516.54M 579.43M
Earning assets - - - - -
Other current assets 27.07M 22.86M 16.92M 24.34M 18.06M
Total liab 672.18M 593.79M 691.72M 646.40M 718.82M
Total stockholder equity 1966.52M 1701.01M 1571.23M 1381.19M 1165.59M
Deferred long term liab 88.98M 98.99M 93.12M 101.09M 89.75M
Other current liab 16.93M 14.48M 13.23M 8.31M 9.16M
Common stock 1.58M 0.39M 0.39M 0.39M 0.38M
Capital stock 1.58M 0.39M 0.39M 0.39M 0.38M
Retained earnings 1309.46M 1122.92M 1085.46M 1057.47M 931.93M
Other liab 99.90M 116.23M 142.99M 110.91M 111.72M
Good will 872.74M 822.10M 843.07M 728.31M 732.67M
Other assets 12.59M 46.83M 11.57M 13.52M 5.67M
Cash 180.57M 172.57M 199.09M 146.62M 100.89M
Cash and equivalents - - - - -
Total current liabilities 128.51M 176.02M 152.28M 106.67M 101.98M
Current deferred revenue 23.07M 23.41M 19.00M 13.05M 9.08M
Net debt 274.39M 153.40M 221.46M 286.90M 404.27M
Short term debt 11.20M 24.43M 24.10M 22.04M 12.50M
Short long term debt - 12.50M 12.50M 12.50M 12.50M
Short long term debt total 454.96M 325.97M 420.55M 433.53M 505.16M
Other stockholder equity 721.54M 652.90M 542.67M 420.54M 316.80M
Property plant equipment 226.20M 288.80M 281.74M 248.29M 154.04M
Total current assets 621.48M 605.56M 510.61M 520.92M 412.61M
Long term investments - - - - -
Net tangible assets 652.90M 347.39M 112.20M 136.34M -146.50700M
Short term investments 23.74M 74.46M 32.46M 124.27M 65.15M
Net receivables 218.47M 194.55M 145.38M 122.53M 137.47M
Long term debt 350.00M 243.41M 328.83M 344.24M 492.66M
Inventory 171.64M 141.12M 116.75M 103.15M 91.05M
Accounts payable 77.31M 113.70M 95.96M 63.27M 71.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - -0.75900M 8.26M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -66.06400M -75.20000M -57.29100M -97.19900M -83.52100M
Additional paid in capital - - - - -
Common stock total equity 1.58M 0.39M 0.39M 0.39M 0.38M
Preferred stock total equity - - - - -
Retained earnings total equity 1309.46M 1122.92M 1085.46M 1057.47M 931.93M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 285.30M -52.16600M 11.57M 13.52M 5.67M
Deferred long term asset charges - - - - -
Non current assets total 2017.21M 1689.25M 1752.35M 1506.67M 1471.80M
Capital lease obligations 104.97M 70.06M 79.23M 76.78M -
Long term debt total 350.00M 243.41M 328.83M 344.24M 492.66M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -265.64900M -96.85100M -243.51600M 76.93M -21.89600M
Change to liabilities -34.95800M 12.74M 19.09M 5.66M 1.59M
Total cashflows from investing activities -265.64900M -96.85100M -243.51600M 27.09M -336.79900M
Net borrowings 94.00M -85.50000M -15.50000M -148.50000M 166.50M
Total cash from financing activities 22.62M -242.85300M -62.55100M -183.80200M 134.38M
Change to operating activities -29.14300M 4.68M 19.43M -0.05300M 4.32M
Net income 285.44M 263.10M 139.59M 229.30M 96.07M
Change in cash 8.00M -26.52400M 52.47M 45.74M -21.10400M
Begin period cash flow 172.57M 199.09M 146.62M 100.89M 121.99M
End period cash flow 180.57M 172.57M 199.09M 146.62M 100.89M
Total cash from operating activities 254.39M 325.27M 352.16M 205.22M 181.62M
Issuance of capital stock - - - - -
Depreciation 107.24M 101.07M 87.75M 82.74M 78.17M
Other cashflows from investing activities -27.96500M -51.94300M -225.90800M 1.91M -289.49200M
Dividends paid 50.28M 50.19M 49.62M 48.90M 48.36M
Change to inventory 0.40M -32.00700M -7.14000M -14.86100M -13.64700M
Change to account receivables -20.86700M -57.59600M -15.54900M 6.56M -2.70000M
Sale purchase of stock -19.56200M -160.95000M -43.17800M -50.11200M -15.40500M
Other cashflows from financing activities 92.46M 143.78M -19.34300M -7.27100M -6.29700M
Change to netincome -37.19700M -47.84800M 94.74M 43.81M 21.06M
Capital expenditures 38.24M 44.91M 44.30M 51.74M 25.41M
Change receivables -20.86700M -57.59600M -15.54900M 6.56M -15.00000M
Cash flows other operating -15.09800M -39.13900M 72.15M -147.98200M 13.37M
Exchange rate changes - - - - -0.30800M
Cash and cash equivalents changes 11.36M -14.43200M 46.10M 48.51M -21.10400M
Change in working capital -48.18700M -69.51700M 29.26M -5.24600M -27.75100M
Stock based compensation 39.23M 42.18M 48.98M 32.37M 32.28M
Other non cash items -99.76300M -18.37800M 74.02M -147.06700M 16.43M
Free cash flow 216.15M 280.36M 307.86M 153.47M 156.21M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TECH
Bio-Techne Corp		 -2.05 3.74% 52.82 64.54 33.67 9.16 5.34 9.53 29.02
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp

614 McKinley Place N.E., Minneapolis, MN, United States, 55413

Key Executives

Name Title Year Born
Mr. Charles R. Kummeth CEO, Pres & Director 1960
Mr. James T. Hippel Exec. VP of Fin. & CFO 1971
Ms. Brenda S. Furlow J.D. Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer 1958
Mr. Kim Kelderman Pres of Diagnostics & Genomics 1967
Mr. William A. Geist Pres of Protein Sciences Segment 1970
David Clair Sr. Director of Investor Relations & Corp. Devel. NA
Mr. Gerry Andros VP of Sales and Marketing NA
Mr. Robert M. Gavin VP of Corp. Devel. 1968
Ms. Brenda S. Everson Sr. VP & Chief HR Officer NA
Mr. Luca Cicchetti Managing Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.